Decreasing Skin Graft Contraction through Topical Wound Bed Preparation with Anti-Inflammatory Agents
Technical Report,15 Sep 2014,14 Sep 2015
The Geneva Foundation Tacoma
Pagination or Media Count:
This proposal aims to identify topically applied anti-inflammatory drugs that will reduce recipient site inflammation and skin graft contraction. We hypothesize that the elevated and prolonged inflammatory state of the recipient wound bed is a causative factor in the development of skin graft contraction. Using a porcine model of skin graft contraction, we will screen for anti-inflammatory agents dose, schedule of administration, drug class that reduce inflammatory cytokines in the recipient wound bed during 6 days post-wounding. We will then validate the effectiveness of the anti-inflammatory agent, dose and schedule to reduce contraction of the grafted split-thickness skin by allowing the experimental animal to survive for a longer period of time. Specifically, the aims of the proposal are to develop treatments that modulate inflammation and decrease skin graft contraction. We will achieve this by 1 identifying a dose and schedule of anti-inflammatory drug that most effectively blocks excessive inflammation of the recipient wound bed as defined by inflammatory markers and 2 validate the schedule and dose of anti-inflammatory drug shown to reduce inflammation of the recipient wound bed to decrease skin graft contraction.